Chimerix, Inc. (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against over five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir is marketed under the brand name Viread. The Company has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CMRX
- Previous Close: $5.68
- 50 Day Moving Average: $5.30
- 200 Day Moving Average: $4.93
- 52-Week Range: $3.49 - $7.73
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.44
- P/E Growth: 0.00
- Market Cap: $256.59M
- Outstanding Shares: 46,315,000
- Beta: 1.62
- Net Margins: -1,451.99%
- Return on Equity: -32.09%
- Return on Assets: -30.80%
Companies Related to Chimerix:
- Current Ratio: 26.47%
- Quick Ratio: 26.47%
What is Chimerix's stock symbol?
Chimerix trades on the NASDAQ under the ticker symbol "CMRX."
Where is Chimerix's stock going? Where will Chimerix's stock price be in 2017?
7 analysts have issued 1 year target prices for Chimerix's stock. Their forecasts range from $5.00 to $12.00. On average, they anticipate Chimerix's share price to reach $7.86 in the next twelve months.
When will Chimerix announce their earnings?
Chimerix is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Chimerix stock?
Here are some recent quotes from research analysts about Chimerix stock:
According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (2/16/2017)
FBR & Co analysts commented, "We recently had an opportunity to meet with CMRX’s management to discuss the company’s outlook for 2017. CMRX updated us on the progress it has made with its pipeline, with several milestones stated for 2017. It is advancing the intravenous (IV) formulation of brincidofovir (BCV) to address CMV, the BK virus, and other DNA viral infections. Additionally, the company updated progress on CMX521, which is in preclinical studies for norovirus. We expect an IND to be filed in the back half of this year." (1/11/2017)
Who owns Chimerix stock?
Chimerix's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), EcoR1 Capital LLC (3.06%), Opaleye Management Inc. (2.53%), Arrowpoint Asset Management LLC (2.26%), State Street Corp (1.62%) and Dimensional Fund Advisors LP (1.05%). Company insiders that own Chimerix stock include Ernest Mario, John M Leonard, M Michelle Berrey, Martha J Demski and Timothy W Trost.
Who sold Chimerix stock? Who is selling Chimerix stock?
Chimerix's stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE and AQR Capital Management LLC. Company insiders that have sold Chimerix stock in the last year include Ernest Mario and John M Leonard.
Who bought Chimerix stock? Who is buying Chimerix stock?
Chimerix's stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Opaleye Management Inc., Dimensional Fund Advisors LP, Arrowpoint Asset Management LLC, Two Sigma Investments LP, Cigna Investments Inc. New, Moloney Securities Asset Management LLC and GSA Capital Partners LLP. Company insiders that have bought Chimerix stock in the last two years include Ernest Mario, John M Leonard, M Michelle Berrey and Martha J Demski.
How do I buy Chimerix stock?
Shares of Chimerix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Chimerix stock cost?
One share of Chimerix stock can currently be purchased for approximately $5.68.